Table 1 Patient clinical variables based on overall survival (OS) in months as short (OS ≤ 7 months), medium (OS > 7months to 18 months), and long-term (OS > 18 months) survivors for the discovery and validation cohort.

From: Mass Effect Deformation Heterogeneity (MEDH) on Gadolinium-contrast T1-weighted MRI is associated with decreased survival in patients with right cerebral hemisphere Glioblastoma: A feasibility study

 

Discovery cohort

Hold-out validation cohort

Short

Medium

Long

Short

Medium

Long

Total

26

35

28

12

21

16

Right Tumor

12

17

12

3

6

10

Left Tumor

14

18

16

9

15

6

Right Tumor Vol (ml)

21.25 ± 17.45

17.50 ± 11.98

11.14 ± 9.60

44.39 ± 29.83

19.51 ± 15.51

39.22 ± 53.96

Left Tumor Vol (ml)

14.69 ± 15.41

10.83 ± 10.07

14.95 ± 11.31

80.63 ± 79.40

26.15 ± 19.23

24.48 ± 6.60

Male (%)

53.8

65.7

64.2

50

71.4

62.5

Median Age (yr)

66.5

59

55.5

60

57.5

58.5

Median KPS

80

80

80

80

80

80

Median Survival (mo)

4.03

12.06

25.56

3.03

11.1

29.14

Mean Survival (mo)

4.18

11.86

31.27

3.59

12.22

32.38

Back to article page